Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5TCZ

NMR solution structure of engineered Protoxin-II analog

Summary for 5TCZ
Entry DOI10.2210/pdb5tcz/pdb
NMR InformationBMRB: 30181
DescriptorBeta/omega-theraphotoxin-Tp2a (1 entity in total)
Functional Keywordsvenom peptide analog, inhibitor, cystine knot, toxin
Biological sourceThrixopelma pruriens (Peruvian green velvet tarantula)
Total number of polymer chains1
Total formula weight3862.72
Authors
Gibbs, A.C.,Wickenden, A.D. (deposition date: 2016-09-16, release date: 2017-01-18, Last modification date: 2024-10-23)
Primary citationFlinspach, M.,Xu, Q.,Piekarz, A.D.,Fellows, R.,Hagan, R.,Gibbs, A.,Liu, Y.,Neff, R.A.,Freedman, J.,Eckert, W.A.,Zhou, M.,Bonesteel, R.,Pennington, M.W.,Eddinger, K.A.,Yaksh, T.L.,Hunter, M.,Swanson, R.V.,Wickenden, A.D.
Insensitivity to pain induced by a potent selective closed-state Nav1.7 inhibitor.
Sci Rep, 7:39662-39662, 2017
Cited by
PubMed Abstract: Pain places a devastating burden on patients and society and current pain therapeutics exhibit limitations in efficacy, unwanted side effects and the potential for drug abuse and diversion. Although genetic evidence has clearly demonstrated that the voltage-gated sodium channel, Nav1.7, is critical to pain sensation in mammals, pharmacological inhibitors of Nav1.7 have not yet fully recapitulated the dramatic analgesia observed in Nav1.7-null subjects. Using the tarantula venom-peptide ProTX-II as a scaffold, we engineered a library of over 1500 venom-derived peptides and identified JNJ63955918 as a potent, highly selective, closed-state Nav1.7 blocking peptide. Here we show that JNJ63955918 induces a pharmacological insensitivity to pain that closely recapitulates key features of the Nav1.7-null phenotype seen in mice and humans. Our findings demonstrate that a high degree of selectivity, coupled with a closed-state dependent mechanism of action is required for strong efficacy and indicate that peptides such as JNJ63955918 and other suitably optimized Nav1.7 inhibitors may represent viable non-opioid alternatives for the pharmacological treatment of severe pain.
PubMed: 28045073
DOI: 10.1038/srep39662
PDB entries with the same primary citation
Experimental method
SOLUTION NMR
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon